全文获取类型
收费全文 | 274191篇 |
免费 | 20335篇 |
国内免费 | 7784篇 |
专业分类
耳鼻咽喉 | 1894篇 |
儿科学 | 10300篇 |
妇产科学 | 3019篇 |
基础医学 | 24602篇 |
口腔科学 | 4628篇 |
临床医学 | 28530篇 |
内科学 | 63610篇 |
皮肤病学 | 3527篇 |
神经病学 | 29797篇 |
特种医学 | 7548篇 |
外国民族医学 | 12篇 |
外科学 | 24186篇 |
综合类 | 35744篇 |
现状与发展 | 33篇 |
一般理论 | 13篇 |
预防医学 | 22606篇 |
眼科学 | 3438篇 |
药学 | 20092篇 |
208篇 | |
中国医学 | 12080篇 |
肿瘤学 | 6443篇 |
出版年
2024年 | 467篇 |
2023年 | 5097篇 |
2022年 | 7345篇 |
2021年 | 14097篇 |
2020年 | 12947篇 |
2019年 | 11489篇 |
2018年 | 11198篇 |
2017年 | 10222篇 |
2016年 | 10106篇 |
2015年 | 9989篇 |
2014年 | 19472篇 |
2013年 | 21464篇 |
2012年 | 16236篇 |
2011年 | 17595篇 |
2010年 | 13492篇 |
2009年 | 12796篇 |
2008年 | 12688篇 |
2007年 | 12040篇 |
2006年 | 10576篇 |
2005年 | 8875篇 |
2004年 | 7682篇 |
2003年 | 6531篇 |
2002年 | 5472篇 |
2001年 | 4775篇 |
2000年 | 4110篇 |
1999年 | 3475篇 |
1998年 | 3231篇 |
1997年 | 2887篇 |
1996年 | 2536篇 |
1995年 | 2325篇 |
1994年 | 2140篇 |
1993年 | 1807篇 |
1992年 | 1697篇 |
1991年 | 1518篇 |
1990年 | 1291篇 |
1989年 | 1075篇 |
1988年 | 1018篇 |
1987年 | 906篇 |
1986年 | 779篇 |
1985年 | 1358篇 |
1984年 | 1281篇 |
1983年 | 822篇 |
1982年 | 979篇 |
1981年 | 860篇 |
1980年 | 671篇 |
1979年 | 607篇 |
1978年 | 507篇 |
1977年 | 412篇 |
1976年 | 386篇 |
1975年 | 315篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
目的:观察川芎茶调散加减方联合针灸治疗周围性面神经麻痹(风寒证)的临床效果。方法:选取2018年2月至2019年2月威海市中医院收治的急性周围性面瘫患者108例作为研究对象,按照随机数字表法分为对照组与观察组,每组54例。对照组给予常规西药治疗,观察组给予川芎茶调散加减方口服联合针灸治疗。比较2组患者主要症状的改善时间、肌电图检查相关指标、面部神经功能分级的变化,测定血清中相关因子水平,比较临床效果。结果:观察组、对照组的有效率92.59%、75.93%,以观察组临床效果更好(P0.05);观察组患者治疗后的闭目、抬眉、鼓颊的改善时间明显短于对照组(P0.05);观察组患者的肌电图结果RI潜伏期低于对照组,CMAP波幅高于对照组,面部神经功能分级改善更明显(P0.05);观察组患者血清中TNF-α、IL-17含量明显低于对照组,GDNF含量显著高于对照组(P0.05)。结论:川芎茶调散加减方联合针灸利于促进患者临床症状的缓解,改善肌电图指标,促进面部神经功能的恢复,推断其起效可能与通过调控血清中TNF-α、GDNF、IL-17等水平以减轻患者神经病变的炎性反应损伤程度有关。 相似文献
72.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
73.
74.
《The Journal for Nurse Practitioners》2019,15(1):65-72
Valvular heart disease affects patients of all ages, with the highest incidence in patients older than 75 years. The nurse practitioner, whether in the primary or acute care setting, plays a vital role in the detection, monitoring, and shared decisions in treatment options. Assessment skills in conjunction with appropriate testing can identify patients early in the trajectory of the disease. The purpose of this article is to provide tips for history-taking and physical exam techniques, identify appropriate diagnostic testing, and review treatment options for adults with valvular heart disease. 相似文献
75.
76.
Alzheimer’s disease is characterized by the extracellular accumulation of the amyloidβin the form of amyloid plaques and the intracellular deposition of the microtubule-associated protein tau in the form of neurofibrillary tangles.Most of the Alzheimer’s drugs targeting amyloidβhave been failed in clinical trials.Particularly,tau pathology connects greatly in the pathogenesis of Alzheimer’s disease.Tau protein enhances the stabilization of microtubules that leads to the appropriate function of the neuron.Changes in the quantity or the conformation of tau protein could affect its function as a microtubules stabilizer and some of the processes wherein it is involved.The molecular mechanisms leading to the accumulation of tau are principally signified by numerous posttranslational modifications that change its conformation and structural state.Therefore,aberrant phosphorylation,as well as truncation of tau protein,has come into focus as significant mechanisms that make tau protein in a pathological entity.Furthermore,the shape-shifting nature of tau advocates to comprehend the progression of Alzheimer’s disease precisely.In this review,we emphasize the recent studies about the toxic and shape-shifting nature of tau in the pathogenesis of Alzheimer’s disease. 相似文献
77.
78.
目的:探究复方丹参滴丸对老年冠心病患者血流变学、血脂及炎性反应递质的影响。方法:选取2015年1月至2017年12月海南省人民医院收治的老年冠心病患者154例作为研究对象,按照随机数字表法随机分为对照组和观察组,每组77例。对照组采用常规西药治疗,观察组在此基础上加服复方丹参滴丸。比较治疗前后2组患者的血流变学、血脂、炎性反应递质和疗效。结果:观察组治疗有效率为92.21%,明显高于对照组治疗有效率79.22%,差异有统计学意义(P<0.05)。治疗后,2组总胆固醇(TC)、三酰甘油(TG)和低密度脂蛋白(LDL)水平均升高,差异有统计学意义(P<0.05),且观察组高于对照组,2组差异有统计学意义(P<0.05)。2组血流变学指标、高密度脂蛋白(HDL)、IL-6和TNF-α水平治疗后均降低(P<0.05),且观察组降低更明显,差异有统计学意义(P<0.05)。结论:复方丹参滴丸联合常规西药治疗冠心病患者,能够调节脂代谢,降低炎性反应,改善血流变学。 相似文献
79.
80.
AimsThe effect of Origanum majorana tea consumption on motor and non-motor symptoms was investigated in patients with idiopathic Parkinson's disease, measured by validated tools.MethodsSixty patients with idiopathic Parkinson's disease and under conventional medication were enrolled voluntarily in the study. All participants were randomized on double-blind to placebo or Origanum majorana. Clinical assessment with validated tools (UPDRSIII, NMSS, and BDI) was done before Origanum majorana or placebo consumption (Day 0) and at the end of the experiment (Day 30).ResultsThe treatment groups were similar at baseline on demographic and clinical variables. During the course of study, nine participants withdrew for reasons of noncompliance and inability to follow-up. Fifty-one participants completed the study. Upon completion of 30 days of treatment, Origanum majorana tea consumption did not decrease the UPDRSIII score ([UPDRSIII] D0 = 18.76 ± 8.58, D30 = 16.52 ± 7.96, p = 0.069) at the p value was 0.07. However, a statistically significant improvement was noted in NMSS and BDI scores (p < 0.0001 and p < 0.0001, respectively). Assessment of the UPDRSIII, NMSS and BDI scores of the patients did not reflect any improvement with placebo. No side effect was detected during the study.ConclusionThese findings show improvement of depressive and non-motor signs in patients with Parkinson's disease in the group that consumed Origanum majorana tea in combination with conventional therapy. Improvement of motor signs may need an extended treatment period. However, more research with a large number of participants and lasting longer than 1 month is needed to argue these findings. 相似文献